
Välj din etikett
visas direkt på vialenReta + Tesamorelin Blend
GLP-1
- Skickas från Tyskland
Beställning
- DHL med spårning
- Diskret förpackning
I korthet
Reta + Tesamorelin Blend i siffror
Nyckeltalen från vårt lexikon.
Hela lexikonartikeln- Type
- Injectable blendtriple agonist + GHRH analog
- Sizes
- 20 mg1 size in the shop
What studies show
All 4 sources in the lexiconRetatrutide phase 2 trial (obesity), 48 weeks, NEJM 2023 (opens in a new tab)
New England Journal of Medicine (PubMed PMID 37366315)Retatrutide systematic review + meta-analysis (878 patients), 2025 (opens in a new tab)
Proc (Bayl Univ Med Cent) (PubMed PMID 40291085)Tesamorelin phase 3 trial (visceral fat, HIV), 12 months (opens in a new tab)
J Acquir Immune Defic Syndr (PubMed PMID 20101189)
Omdömen
Vad kunderna säger
Endast riktiga beställningar som innehöll Reta + Tesamorelin Blend.
Alla omdömenDet finns ännu ingen labbanalys för Reta + Tesamorelin Blend. Rösta på denLåt testa själv, vi betalar halvaAlla labbanalyser
Kunskap
Allt om Reta + Tesamorelin Blend
Detaljerad information kommer snart.
Dosering
Laddar doseringsinformation …
Bra att ha
Vad du behöver till den
Bakteriostatiskt vatten läggs automatiskt i din varukorg. Sprutor och sudd med ett klick.
Insulinsprutor
10 st. · 5.50 €
Spritsuddar
50 st. · 10 €
Hur mycket vatten?
Enheter på sprutan för din vialstorlek.
Öppna kalkylatorn →Is the Reta + Tesamorelin Blend approved or studied?
No. As of 26 October 2026 the registry ClinicalTrials.gov lists no trial with Retatrutide and tesamorelin together. Tesamorelin alone has been approved in the USA since 2010, Retatrutide is in phase 3 and not approved.
What is the catch with the fixed mix?
The two substances were studied on very different schedules: Retatrutide once a week, tesamorelin daily. In a 1:1 vial the ranges from both trial programmes cannot be matched at the same time. The entry therefore goes by the Retatrutide share.
What do the Retatrutide trials show?
In phase 2 body weight fell by 24.2 percent after 48 weeks at the highest study dose, by 2.1 percent on placebo. In phase 3 (TRIUMPH-1) it was 25.0 versus 3.9 percent after 80 weeks. A meta-analysis with 878 participants confirmed clear effects on weight and metabolic values.
What do the tesamorelin trials show?
In 806 patients with HIV and excess belly fat, visceral fat fell by 15.4 percent more than on placebo in 26 weeks, subcutaneous fat stayed nearly the same. IGF-1 rose, blood sugar stayed stable. Those who continued kept the effect to week 52.
Which side effects were seen with the components?
Retatrutide: mainly nausea, diarrhoea and other gastrointestinal effects, depending on the dose, plus a slight rise in heart rate. Tesamorelin: injection site reactions, joint and muscle pain, fluid retention and tingling. There is no safety profile for the blend.
Which trials are still running?
Nine phase 3 trials of Retatrutide are running, the largest on heart and kidney events until 2029. The phase 3 trials of tesamorelin were completed years ago. No trial of the blend is listed in the registry.
Relaterat
Relaterade produkter
Tirzepatide
Peptider · GLP-1 & fettförbränning GLP-1 & fettförbränning
10 storlekar
Labbtestad
= från 10 €/vial
Retatrutide
Peptider · GLP-1 & fettförbränning GLP-1 & fettförbränning
11 storlekar
Labbtestad
= från 16 €/vial
Semaglutide
Peptider · GLP-1 & fettförbränning GLP-1 & fettförbränning
6 storlekar
Labbtestad
= från 10 €/vial
Mazdutide
Peptider · GLP-1 & fettförbränning GLP-1 & fettförbränning
2 storlekar
= från 32 €/vial
Reta + Tesamorelin Blend